Sarcoidosis Immunotsuppressive Therapy… | Clinical Trial

Key information

Conditions

Sarcoidosis Lung Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity, Delayed Immune System Diseases Immunoproliferative Disorders Lung Diseases Lung Diseases, Interstitial Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Respiratory Tract Diseases Sarcoidosis Sarcoidosis, Pulmonary

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Alexandria main university hospital

Alexandria, Asafra, 11511, Egypt

About this study

This is a prospective observational cohort study to be conducted in the Chest Diseases Department, Alexandria Main University Hospital. A total of 40 adult patients (≥16 years) with biopsy-proven sarcoidosis will be consecutively recruited between December 2024 and December 2025. All patients will be either newly starting or continuing immunosuppressive therapy for sarcoidosis. The treatment regimen-systemic corticosteroids, conventional steroid-sparing agents (methotrexate, azathioprine, or mycophenolate), or biologics (anti-TNF agents)-will be recorded but not altered by study design. Each patient will be followed prospectively for 12 months from enrollment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria include adult patients (≥18 years) with histologically confirmed sarcoidosis, receiving or planned to receive immunosuppressive therapy

Exclusion criteria

Patients with a prior history of lymphoma or other active malignancy, HIV infection, or other primary immunodeficiency will be excluded.

-

Treatment and study plan

lymph node biopsy

Procedure

sarcoidosis diagnosis by lymph node biopsy excisiona or bronchoscopic

Primary outcomes

The primary outcome will be incident, biopsy-proven lymphoma during the 12-month follow-up.

Time frame: 12 MONTHS

LYMPH NODE BIOPSY EITHER EXCISIONAL OR BRONCHOSCOPIC
lymphoma development

Time frame: 12 months

lymph node biopsy excisional or bronchoscopic

Sponsors and collaborators

Lead sponsor

Alexandria University

Other

Registry information

Official study title

Impact of Immunosuppressive Therapy of Sarcoidosis on Lymphoma Development

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2026
First posted: Jan 15, 2026
Registry last updated: Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed